Search: id:"swepub:oai:DiVA.org:kth-214502" >
The effect of the T...
The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C : a meta-analysis
-
- Liu, Zhengtao (author)
- KTH,Science for Life Laboratory, SciLifeLab,Kungliga Tekniska Högskolan (KTH),Royal Institute of Technology (KTH),Zhejiang University
-
Que, Shuping (author)
-
- Zhou, Lin (author)
- Zhejiang University
-
show more...
-
- Zheng, Shusen (author)
- Zhejiang University
-
- Romeo, Stefano, 1976 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberglaboratoriet,Institute of Medicine, Department of Molecular and Clinical Medicine,Wallenberg Laboratory,Universita degli studi Magna Graecia di Catanzaro,Magna Græcia University,University of Gothenburg
-
- Mardinoglu, Adil (author)
- KTH,Science for Life Laboratory, SciLifeLab,Chalmers tekniska högskola,Chalmers University of Technology
-
- Valenti, Luca (author)
- Universita' degli Studi di Milano,University of Milan,Ospedale Maggiore Policlinico Milano
-
show less...
-
(creator_code:org_t)
- 2017-08-24
- 2017
- English.
-
In: Scientific Reports. - : Nature Publishing Group. - 2045-2322. ; 7
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://www.nature.c...
-
http://publications.... (primary) (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://gup.ub.gu.se...
-
https://research.cha...
-
show less...
Abstract
Subject headings
Close
- The impact of Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant, which causes hepatocellular fat retention by altering lipoprotein secretion, on liver damage and metabolic traits in chronic hepatitis C patients is still debated. We performed a systematic review and meta-analysis to clarify this relationship. Four studies with a total of 4325 patients were included. The risk of histologically-determined advanced steatosis, fibrosis, and cirrhosis (but not of severe inflammation) were increased in carriers of the TM6SF2 variant (P < 0.05). Unlike the inconsistent association with steatosis severity, due to the confounding effect of infection by the genotype-3 hepatitis C virus, the TM6SF2 variant was robustly associated with advanced fibrosis (OR = 1.07; 95% confidence interval [CI] = 1.01-1.14) and in particular with cirrhosis (OR = 2.05; 95% CI = 1.39-3.02). Regarding metabolic features, individuals positive for the TM6SF2 variant exhibited 5.8-12.0% lower levels of circulating triglycerides and non-HDL cholesterol (P < 0.05). Carriers of the variant were leaner, but there was high heterogeneity across studies (I-2 = 97.2%). No significant association was observed between the TM6SF2 variant and insulin resistance or hepatitis C viral load (both P > 0.05). In conclusion, the TM6SF2 E167K variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis C. Conversely, this variant reduces circulating atherogenic lipid fractions.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database